Evaluating zasocitinib as an oral therapy for moderate to severe plaque psoriasis.

McGuirt V, Razler D, Moore SG, Feldman S

DOI: 10.1080/14656566.2026.2714835
Published: 2026 Aug
Container: Expert opinion on pharmacotherapy
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14656566.2026.2714835,
  title = {Evaluating zasocitinib as an oral therapy for moderate to severe plaque psoriasis.},
  author = {McGuirt V and Razler D and Moore SG and Feldman S},
  year = {2026},
  journal = {Expert opinion on pharmacotherapy},
  doi = {10.1080/14656566.2026.2714835},
  url = {https://doi.org/10.1080/14656566.2026.2714835}
}

RIS

TY  - JOUR
TI  - Evaluating zasocitinib as an oral therapy for moderate to severe plaque psoriasis.
AU  - McGuirt V
AU  - Razler D
AU  - Moore SG
AU  - Feldman S
PY  - 2026
JO  - Expert opinion on pharmacotherapy
DO  - 10.1080/14656566.2026.2714835
UR  - https://doi.org/10.1080/14656566.2026.2714835
ER  -

APA

V, M., D, R., SG, M., & S, F. (2026). Evaluating zasocitinib as an oral therapy for moderate to severe plaque psoriasis.. Expert opinion on pharmacotherapy. https://doi.org/10.1080/14656566.2026.2714835

Source records

pubmed · retrieved 2026-09-25T20:51:21.457Z
europe-pmc · retrieved 2026-09-25T20:51:21.475Z